Summary & Overview
HCPCS Level II M1206: Itch Severity Follow-Up Assessment Not Improved
HCPCS Level II code M1206 documents that an itch severity assessment either was not completed at a follow-up encounter or did not improve by at least 3 points from the initial score. As a measure of treatment response or care process, this code matters nationally because it signals the need to track symptom persistence, treatment effectiveness, and follow-up quality in dermatology and related outpatient settings. The analysis covers key national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find clinical context for what the code represents, typical service settings, and what this indicator communicates about patient outcomes. The publication also outlines common billing modifiers and highlights where data was not provided. The content aims to clarify coding intent, explain typical use in follow-up assessments for pruritus, and summarize the kinds of benchmarks and policy considerations that payers and providers monitor for outcome-based coding. Data not available in the input: associated taxonomies, ICD-10 diagnoses, related codes, and service line details.
Billing Code Overview
HCPCS Level II code M1206 indicates that an itch severity assessment score was not reduced by at least 3 points from the initial (index) score to the follow-up visit score or that the assessment was not completed during the follow-up encounter. This code captures follow-up evaluation outcomes for patients being monitored for pruritus or related dermatologic symptoms.
-
Service type: Follow-up outcome assessment for itch severity
-
Typical site of service: Outpatient clinic or ambulatory care follow-up visit
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with chronic pruritus secondary to atopic dermatitis presents for a scheduled dermatology follow-up visit two months after initiating therapy. At the index visit the clinician documented an itch severity score (for example, a validated patient-reported numeric rating scale) of 7/10. At the follow-up visit the clinician documents a score of 6/10, which does not represent a reduction of at least 3 points from the index score. The follow-up encounter includes a focused history of response to therapy, medication adherence review, medication adverse effect screening, and consideration of therapy adjustment. The clinician documents the itch severity assessment but documents that the required improvement threshold (≥3-point reduction) was not met; alternatively, the clinician may have omitted completion of the itch severity assessment during the follow-up encounter. Billing for M1206 is used to indicate that the itch severity assessment score did not reduce by at least 3 points from baseline or the assessment was not completed during the follow-up visit. Typical sites of service include dermatology outpatient clinics, wound care centers, infusion centers for biologic therapy, and primary care or allergy clinics managing chronic pruritus. Typical patient scenarios include treatment monitoring for atopic dermatitis, chronic urticaria, prurigo nodularis, or systemic causes of chronic itch where serial patient-reported itch severity scores are part of outcome measurement and quality reporting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |